Wells Fargo lowered the firm’s price target on Oscar Health (OSCR) to $11 from $14 on lower odds for enhanced subsidy extension, while keeping an Underweight rating on the shares. The firm is updating estimates and model assumptions following Q3 and greater visibility into 2026 market dynamics. Wells sees Oscar Health as a clear share gainer in 2026, making it harder to underwrite MLR improvement.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Cautious Outlook on Oscar Health: Sell Rating Amid Uncertain Profitability and Market Dynamics
- OSCR, ELV, CNC: Health Insurer Stocks on Watch as Trump Pushes ACA Funds Directly to Americans
- Oscar Health falls -14.3%
- Oscar Health price target raised to $13 from $11 at Barclays
- Oscar Health’s Earnings Call: Growth Amid Challenges